DNAVision Announces Distribution Agreement with Eurogentec
News Feb 07, 2006
DNAVision and Eurogentec have announced that they have a distribution agreement under which Eurogentec will produce and market real-time PCR kits for the quantitation of 200 premature MicroRNA. This quantitation tool has been developed by DNAVision and validated by Eurogentec.
The quantitation of the precursors miRNA expression will help the understanding of the miRNA functions. Up-regulation of the miRNAs can help to identify gain-of-function phenotypes while down-regulation or inhibition studies can help to identify loss-of-function phenotypes.
The combination of up- and down-regulation can be used to identify not only genes that are regulated by miRNAs but also cellular processes that are affected by specific miRNAs.
"We are delighted to offer this tool to quantitate premature MicroRNA and to point out the entrance of Eurogentec in this new market," said Daniel Marechal, Product and Business Development Manager of Eurogentec.
Jean-Pol Detiffe, CEO of DNAVision was equally enthusiastic as he declared that, "this agreement is probably the starting point for a synergetic partnership between our two companies and it will strengthen our MicroRNA quantification services for researchers all over the world."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.